ClinicalTrials.gg
TerminatedNCT01078376Updated Jul 25, 2014Results posted

A Comparative Single-Dose Pharmacokinetic (PK) and Safety Study of Azilsartan Medoxomil in Children With Hypertension and in Healthy Adults

A Phase 1 interventional study of Azilsartan medoxomil (TAK-491) and Azilsartan medoxomil (TAK-491) in Hypertension, sponsored by Takeda. Terminated at 8 sites in 2 countries. Open to participants aged 1 Year to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-25.

Sponsored by Takeda · Phase 1 and Interventional

Why this study was terminated
Business Decision (see below)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Non-randomized
Ages
1 Year to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing azilsartan medoxomil in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. azilsartan medoxomil · Hypertension.

Enrollment
20th of 21
29 · median 566
Started
2010
with 1 other
Phase 1
2 of 21
1 open now
Registered
16th of 21
by date
Lead sponsor
19 of 21
Takeda

Among the 21 studies testing azilsartan medoxomil in Hypertension, this one is the 20th largest by enrollment, is one of 2 that started in 2010, is one of 2 in phase 1, and was the 16th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 21 studies testing azilsartan medoxomil in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 1 Year to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing azilsartan medoxomil in Hypertension, or all of them as a file.
02

Study summary

The purpose of this study was to assess the pharmacokinetics (PK) and safety of a single dose of azilsartan medoxomil in children with hypertension, and comparative PK in healthy adults.

Read the detailed description

Within the past 10 years, the incidence of high blood pressure (hypertension) in children and adolescents has increased all over the world. This increase is connected in part to a growing number of people who are overweight and do not eat right or exercise enough. In younger children though, high blood pressure is a common consequence of underlying diseases, such as renal diseases.

This study looked at a blood pressure medicine called TAK-491 (azilsartan medoxomil) to see how it works in children who have hypertension. Azilsartan medoxomil is a prodrug that converts into TAK-536 (azilsartan), a blood pressure lowering medicine that had not been tested in children.

To be eligible to take part in this study, children with a diagnosis of hypertension (primary or secondary) must have been between the ages of 1 year and 16 years old (up to their 17th birthday). Each child was given one dose of azilsartan medoxomil, followed by a number of blood tests and assessments within 24 hours after taking azilsartan medoxomil to see how the medication is working. Adults who do not have hypertension also took part in this study to provide comparison.

This study took place in 9 sites in the UK and USA. A total of 20 children with hypertension and 9 adults without hypertension participated in this study.

This study lasted about 43 days. This included a 28 day screening period, a 2 day treatment phase and a follow up period. Each participant taking part in this study may have been requested to remain in a hospital for one overnight stay during the course of the study. Each participant was contacted by telephone 6 days and 15 days after taking azilsartan medoxomil.

Takeda has decided to close Cohort 3 (participants between 1 and 6 years of age with hypertension) enrollment early and end this study with the agreement of both the US Food and Drug Administration (FDA) and the Pediatric Committee (PDCO) at the European Medicines Agency. Requests to the FDA and PDCO were submitted to close the study without completion of enrollment in Cohort 3 due to difficulty enrolling this particular patient population. Takeda proposed an alternative option to collect PK data in this age subset by utilizing PK modeling to determine the appropriate doses in children 1-5 years of age in lieu of completing Cohort 3. The FDA and PDCO agreed with this approach.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Pediatrics
  • Blood Pressure, High
  • Drug Therapy
04

Who can participate

Ages eligible
1 Year to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Pediatric Participants:

Must have a diagnosis of hypertension (SBP and/or DBP ≥95th percentile for age/gender/height).

  • For Cohorts 1 and 2 only, is within the weight range of 20 kg (44 pounds) to 100 kg (220 pounds), inclusive, at Screening.
  • For Cohort 3 only, weighs at least 8.0 kg (17.6 pounds) at Screening.
  • Participants greater than or equal to 6 years of age must have the ability to swallow a tablet of the size 6.0 millimeter diameter and 3.5 millimeter thickness.
  • Has no known history of , , and .
  • For Cohort 3 only, may be renal transplant patient if all other inclusion and none of the exclusion criteria are met, along with additional criteria.
  • Must have been at a constant weight, or expected weight gain for that particular age, for 30 days with no change to the dose of their diuretic drugs.

For Healthy Adult Participants:

  • Weighs at least 50 kilograms (110 pounds) and has a screening between 18 and 32 kilograms/m2, inclusive.
  • Is in good health as determined by the physician
  • Has a negative test result for hepatitis B surface antigen and antibody to hepatitis C virus, and has no known history of human immunodeficiency virus.
  • Must have a negative urine test result for selected substances of abuse .
  • Has a diastolic blood pressure between 60 and 90 mm Hg, inclusive, and a systolic blood pressure between 100 and 140 mm Hg, inclusive.

For All Participants:

  • Females of child bearing potential who are sexually active, as well as sexually active male participants, agree to routinely use adequate from Screening until 30 days after receiving the last dose of study medication.
  • Has clinical laboratory results within the reference range for the testing laboratory unless the results are deemed not by the investigator.

Exclusion criteria

Exclusion Criteria:

For Pediatric Participants:

  • Is currently treated with more than 2 antihypertensive agents.
  • Has sitting trough clinic systolic blood pressure greater than 15 mm Hg or diastolic blood pressure greater than 10 mm Hg above the 99th percentile for age, gender, and height at Check-in .
  • Has renovascular disease affecting both kidneys or a solitary kidney, dialysis treatment, severe nephrotic syndrome and not in remission.
  • For Cohort 1 and 2 only, a previous renal transplant.
  • Has a less than 30 mL/min/1.73 m2.

For all participants:

  • Has previously received azilsartan or azilsartan medoxomil.
  • Has a known or allergy to any angiotensin type II receptor blockers or to any of the in the azilsartan medoxomil formulation to be taken.
  • Has a history or clinical manifestations of severe cardiovascular disease, psychiatric disease, and any conditions that would interfere with gastrointestinal absorption.
  • Has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease, cardiomyopathy, or uncorrected coarctation of the aorta.
  • Has been diagnosed with malignant or accelerated hypertension.
  • Has severe hepatic impairment.
  • Has a serum albumin less than 2.5 g/dL.
  • Has a glycosylated value greater than 8.5%.
  • Has , aspartate aminotransferase greater than 2 times the , or total greater than 1.5 times the upper limit of normal, active liver disease, or jaundice.
  • Has hyperkalemia as defined by the laboratory normal reference range or any pertinent electrolyte disorders.
  • Is participating in another study or has taken an investigational drug within 30 days prior to Check-in .
  • Has a history of drug abuse or a history of alcohol abuse within 1 year prior to study Check-in.
  • Has a history of abdominal surgery or thoracic or nonperipheral vascular surgery within 6 months prior to study Check-in.
  • Has a history of cancer, other than basal cell carcinoma or stage I squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to study Check-in.
  • Has taken any cytotoxic drugs within 12 months prior to study Check-in .
  • Has a history or presence of a abnormal 12-lead as determined by the investigator or sponsor/designee.
  • Has poor peripheral venous access.
  • Has any other condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study.
  • Has taken or requires the use of any medications, supplements, or food products within the stated time periods, including:

    • Pediatric participants taking angiotensin-converting enzyme inhibitors and other angiotensin II receptor blockers will be required to withhold these medications from the morning of Day -1 until the 24 hour pharmacokinetic sample is completed on Day 2.
    • Only pediatric participants will be allowed to take medications for primary renal or urologic conditions or hypertension as long as they have been on a stable dose of their medication for at least 30 days prior to Check-in (Day -1) and those medications are not potent cytochrome P-450 inhibitors or inducers.
    • Nutraceuticals including herbal or dietary preparations such as ginseng, kava kava, and ginkgo biloba.
    • Over-the-counter medications.
    • Vitamin supplements except for pediatric participants only.
    • Alcohol-containing products.
    • Products that contain caffeine or xanthine-related compounds.
    • Foods or beverages containing grapefruit juice or Seville-type oranges.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Cohort 1: Healthy Adults (18 years to 45 years old)

    Azilsartan medoxomil 80 mg, tablets, orally, one day only

    Drug: Azilsartan medoxomil (TAK-491)

  • Experimental
    Cohort 1: Adolescents (≥12 to <17 years old)

    Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only

    Drug: Azilsartan medoxomil (TAK-491)

  • Experimental
    Cohort 2: Children (≥6 to <12 years old)

    Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only

    Drug: Azilsartan medoxomil (TAK-491)

  • Experimental
    Cohort 3: Children (≥1 to <6 years old)

    Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only

    Drug: Azilsartan medoxomil (TAK-491)

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536

    AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).

    Time frame: Day 1

  2. Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 Metabolite M-II.

    AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).

    Time frame: Day 1

  3. Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536

    Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.

    Time frame: Day 1

  4. Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 Metabolite M-II

    Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.

    Time frame: Day 1

  5. Maximum Observed Plasma Concentration (Cmax) for TAK-536

    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

    Time frame: Day 1

  6. Maximum Observed Plasma Concentration (Cmax) for TAK-536 Metabolite M-II

    Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

    Time frame: Day 1

  7. Time to Reach Cmax (Tmax) for TAK-536

    Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.

    Time frame: Day 1

  8. Time to Reach Cmax (Tmax) for TAK-536 Metabolite M-II

    Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.

    Time frame: Day 1

  9. Terminal Elimination Half-life (T1/2) for TAK-536

    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

    Time frame: Day 1

  10. Terminal Elimination Half-life (T1/2) for TAK-536 Metabolite M-II

    Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

    Time frame: Day 1

  11. Apparent Oral Clearance (CL/F) for TAK-536

    CL/F is apparent clearance of the drug from the plasma, expressed in L/hr.

    Time frame: Day 1

  12. Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)

    Time frame: Day 1

  13. Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)

    Time frame: Day 1

  14. Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)

    Fe=\[Ae(0-24)/dose\]×100 (molecular weight adjusted for metabolites.

    Time frame: Day 1

  15. Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)

    Fe=\[Ae(0-24)/dose\]×100 (molecular weight adjusted for metabolites.

    Time frame: Day 1

  16. Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)

    Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).

    Time frame: Day 1

  17. Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)

    Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).

    Time frame: Day 1

07

Results

Posted Jul 25, 2014
Limitations and caveats
The study was discontinued without complete enrollment of Cohort 3. Therefore, PK modeling will be used to determine the appropriate doses in children 1 to \<6 years of age, in lieu of completing Cohort 3.

Participant flow

Participants took part in the study at 6 sites in the United States and 3 sites in the United Kingdom from 10 May 2010 to 10 July 2013.

Participant flow — Overall Study
MilestoneCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mgCohort 2: Children (≥6 to <12 Years Old) 20-60 mgCohort 3: Children (≥1 to <6 Years Old)
Started9983
Completed9983
Not completed0000

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536

AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).

Time frame:
Day 1
Reported as:
Mean · ng.hr/mL
Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536
ng.hr/mLCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mgCohort 3: Children (≥1 to <6 Years Old)
Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-53640613 ± 9609.623889 ± 5383.817423 ± 3559.716056 ± NA22556 ± 5792.618691 ± 5489.916963 ± 4948.4
PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 Metabolite M-II.

AUC(0-tlqc) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC\[0-tlqc\]).

Time frame:
Day 1
Reported as:
Mean · ng.hr/mL
Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 Metabolite M-II.
ng.hr/mLCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mgCohort 3: Children (≥1 to <6 Years Old)
Area Under the Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC[0-tlqc]) for TAK-536 Metabolite M-II.11563 ± 3106.57409 ± 78.67428 ± 2120.77392 ± NA7929 ± 3502.69130 ± 1338.37285 ± 3626.0
PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536

Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.

Time frame:
Day 1
Reported as:
Mean · ng.hr/mL
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536
ng.hr/mLCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mgCohort 3: Children (≥1 to <6 Years Old)
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-53644820 ± 11680.726411 ± 6703.118686 ± 3720.416563 ± NA23792 ± 6157.019543 ± 6181.117771 ± 5263.1
PrimaryArea Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 Metabolite M-II

Area under the plasma concentration-time curve from time 0 to infinity, calculated as AUC(0-inf)=AUC(0-tlqc) + Clast/λz.

Time frame:
Day 1
Reported as:
Mean · ng.hr/mL
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 Metabolite M-II
ng.hr/mLCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mgCohort 3: Children (≥1 to <6 Years Old)
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) for TAK-536 Metabolite M-II19188 ± 6766.010596 ± 1168.812532 ± 3905.38961 ± NA11387 ± 5440.714230 ± 3419.69477 ± 4659.6
PrimaryMaximum Observed Plasma Concentration (Cmax) for TAK-536

Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Time frame:
Day 1
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for TAK-536
ng/mLCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mgCohort 3: Children (≥1 to <6 Years Old)
Maximum Observed Plasma Concentration (Cmax) for TAK-5365699 ± 1346.13245 ± 106.12512 ± 701.62810 ± NA3858 ± 1363.02960 ± 364.33320 ± 656.0
PrimaryMaximum Observed Plasma Concentration (Cmax) for TAK-536 Metabolite M-II

Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.

Time frame:
Day 1
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) for TAK-536 Metabolite M-II
ng/mLCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mgCohort 3: Children (≥1 to <6 Years Old)
Maximum Observed Plasma Concentration (Cmax) for TAK-536 Metabolite M-II736 ± 241.6480 ± 74.2535 ± 200.2514 ± NA561 ± 211.7561 ± 40.3488 ± 212.2
PrimaryTime to Reach Cmax (Tmax) for TAK-536

Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.

Time frame:
Day 1
Reported as:
Median · hr
Time to Reach Cmax (Tmax) for TAK-536
hrCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mgCohort 3: Children (≥1 to <6 Years Old)
Time to Reach Cmax (Tmax) for TAK-5362.00 ± 0.88192.01 ± 0.01182.00 ± 0.40822.00 ± NA2.00 ± 2.20432.00 ± 0.00961.00 ± 0.0000
PrimaryTime to Reach Cmax (Tmax) for TAK-536 Metabolite M-II

Tmax: Time to reach the maximum plasma concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 1.

Time frame:
Day 1
Reported as:
Median · hr
Time to Reach Cmax (Tmax) for TAK-536 Metabolite M-II
hrCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mgCohort 3: Children (≥1 to <6 Years Old)
Time to Reach Cmax (Tmax) for TAK-536 Metabolite M-II6.00 ± 1.42275.00 ± 1.41426.00 ± 0.82566.00 ± NA4.03 ± 1.98904.00 ± 2.30946.0 ± 0.0000
PrimaryTerminal Elimination Half-life (T1/2) for TAK-536

Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

Time frame:
Day 1
Reported as:
Mean · hr
Terminal Elimination Half-life (T1/2) for TAK-536
hrCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mgCohort 3: Children (≥1 to <6 Years Old)
Terminal Elimination Half-life (T1/2) for TAK-5367.35 ± 1.0837.74 ± 0.6215.76 ± 1.1585.07 ± NA5.75 ± 0.7605.37 ± 0.9224.59 ± 1.627
PrimaryTerminal Elimination Half-life (T1/2) for TAK-536 Metabolite M-II

Terminal phase elimination half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma.

Time frame:
Day 1
Reported as:
Mean · hr
Terminal Elimination Half-life (T1/2) for TAK-536 Metabolite M-II
hrCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mgCohort 3: Children (≥1 to <6 Years Old)
Terminal Elimination Half-life (T1/2) for TAK-536 Metabolite M-II16.60 ± 6.87012.78 ± 2.91514.00 ± 2.4148.50 ± NA11.56 ± 3.31413.97 ± 2.98310.35 ± 2.770
PrimaryApparent Oral Clearance (CL/F) for TAK-536

CL/F is apparent clearance of the drug from the plasma, expressed in L/hr.

Time frame:
Day 1
Reported as:
Mean · L/hr
Apparent Oral Clearance (CL/F) for TAK-536
L/hrCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mgCohort 3: Children (≥1 to <6 Years Old)
Apparent Oral Clearance (CL/F) for TAK-5361.52 ± 0.4141.88 ± 0.4771.78 ± 0.4112.90 ± NA1.43 ± 0.4270.87 ± 0.2320.54 ± 0.134
PrimaryTotal Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)
Time frame:
Day 1
Reported as:
Mean · mg
Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)
mgCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mg
Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)10.65 ± 4.6734.56 ± 1.0292.89 ± 0.9364.59 ± NA3.63 ± 2.1251.27 ± 0.580
PrimaryTotal Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)
Time frame:
Day 1
Reported as:
Mean · mg
Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)
mgCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mg
Total Amount of Drug Excreted in Urine From Time 0 to 24 Hours Postdose (Ae[0-t]) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)6.60 ± 5.1492.93 ± 0.5822.73 ± 1.5284.43 ± NA2.77 ± 1.1971.48 ± 0.284
PrimaryFraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)

Fe=\[Ae(0-24)/dose\]×100 (molecular weight adjusted for metabolites.

Time frame:
Day 1
Reported as:
Mean · percent
Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)
percentCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mg
Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)16.65 ± 7.3029.50 ± 2.1449.04 ± 2.9259.57 ± NA11.36 ± 6.6397.94 ± 3.622
PrimaryFraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)

Fe=\[Ae(0-24)/dose\]×100 (molecular weight adjusted for metabolites.

Time frame:
Day 1
Reported as:
Mean · percent
Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)
percentCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mg
Fraction of Unchanged Drug Excreted in Urine From 0 to 24 Hours Postdose (Fe%) (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)11.01 ± 8.5816.55 ± 1.2939.11 ± 5.0949.85 ± NA9.22 ± 3.9919.89 ± 1.896
PrimaryRenal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)

Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).

Time frame:
Day 1
Reported as:
Mean · L/hr
Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)
L/hrCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mg
Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536)0.28 ± 0.1300.22 ± 0.0510.17 ± 0.0770.29 ± NA0.15 ± 0.0690.07 ± 0.011
PrimaryRenal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)

Renal clearance, calculated as CLr=Ae(0-24)/AUC(0-24).

Time frame:
Day 1
Reported as:
Mean · L/hr
Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)
L/hrCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 60 mgCohort 1: Adolescents (≥12 to <17 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 60 mgCohort 2: Children (≥6 to <12 Years Old) 40 mgCohort 2: Children (≥6 to <12 Years Old) 20 mg
Renal Clearance (CLr) From 0 to 24 Hours Postdose (for Cohorts 1 and 2 Urine Pharmacokinetic Endpoint for TAK-536 Metabolite M-II)0.55 ± 0.3090.37 ± 0.0840.34 ± 0.1460.60 ± NA0.36 ± 0.0990.16 ± 0.022

Adverse events

Collected over A treatment-emergent adverse event (TEAE) had an onset occurring after the first dose of study medication and within 14 days after the last dose of study medication or, if an SAE, within 30 days after last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Healthy Adults—0/9 (0%)2/9 (22.2%)
Cohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mg—0/9 (0%)5/9 (55.6%)
Cohort 2: Children (≥6 to <12 Years Old) 20-60 mg—0/8 (0%)3/8 (37.5%)
Cohort 3: Children (≥1 to <6 Years Old)—0/3 (0%)0/3 (0%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mgCohort 2: Children (≥6 to <12 Years Old) 20-60 mgCohort 3: Children (≥1 to <6 Years Old)
Abdominal discomfortGastrointestinal disorders0/92/90/80/3
HeadacheNervous system disorders0/92/91/80/3
Infusion site painGeneral disorders0/90/91/80/3
SinusitisInfections and infestations0/90/91/80/3
ArthralgiaMusculoskeletal and connective tissue disorders0/90/91/80/3
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/90/91/80/3
Sinus bradycardiaCardiac disorders1/90/90/80/3
Infected bitesInfections and infestations1/90/90/80/3
DizzinessNervous system disorders0/91/90/80/3
MigraineNervous system disorders0/91/90/80/3

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mgCohort 2: Children (≥6 to <12 Years Old) 20-60 mgCohort 3: Children (≥1 to <6 Years Old)Total
Mean28.3 ± 7.7814.2 ± 1.649.1 ± 2.104.7 ± 0.5816.2 ± 9.81
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mgCohort 2: Children (≥6 to <12 Years Old) 20-60 mgCohort 3: Children (≥1 to <6 Years Old)Total
Female225211
Male773118
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mgCohort 2: Children (≥6 to <12 Years Old) 20-60 mgCohort 3: Children (≥1 to <6 Years Old)Total
Hispanic or Latino40105
Not Hispanic or Latino575320
Not Reported02204
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Cohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mgCohort 2: Children (≥6 to <12 Years Old) 20-60 mgCohort 3: Children (≥1 to <6 Years Old)Total
Asian00101
Black or African American12227
White875121
Height
Height(cm)Cohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mgCohort 2: Children (≥6 to <12 Years Old) 20-60 mgCohort 3: Children (≥1 to <6 Years Old)Total
Mean172.6 ± 9.70163.1 ± 11.72138.6 ± 12.74107.7 ± 11.06153.6 ± 23.45
Weight
Weight(kg)Cohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mgCohort 2: Children (≥6 to <12 Years Old) 20-60 mgCohort 3: Children (≥1 to <6 Years Old)Total
Mean74.64 ± 11.20771.71 ± 15.51248.50 ± 22.52318.30 ± 4.02660.69 ± 23.859
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Cohort 1: Healthy AdultsCohort 1: Adolescents (≥12 to <17 Years Old) 40-60 mgCohort 2: Children (≥6 to <12 Years Old) 20-60 mgCohort 3: Children (≥1 to <6 Years Old)Total
Mean25.06 ± 3.34527.22 ± 6.61124.29 ± 8.32715.67 ± 0.55124.54 ± 6.625
08

Study locations

8 sites
  • Little Rock, Arkansas, United States
  • Atlanta, Georgia, United States
  • Louisville, Kentucky, United States
  • Toledo, Ohio, United States
  • Birmingham, England, United Kingdom
  • Bristol, England, United Kingdom
  • London, England, United Kingdom
  • Manchester, England, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Jul 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2010
First posted
Mar 2, 2010
Start
May 2010
Primary completionActual
Jul 2013
CompletionActual
Sep 2013
Results first posted
Jul 25, 2014
Last update
Jul 25, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01078376
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 2, 2010
Start date
May 2010
Primary completion
Jul 2013
Completion
Sep 2013
Results posted
Jul 25, 2014
Last update
Jul 25, 2014

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azilsartan medoxomil

Start the discussion